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In the past few years the search for an effective method of palliative treatment with a low rate of complications and suitable for the treatment of incurable malignant oesophageal stenoses had led to the development and clinical application of various types of self expanding metal endoprostheses.1-13 Most reports concerned the Wallstent endoprosthesis version.2 3 6 8 12 But first clinical experiences with stents made of memory metal (nitinol) have also been reported.' 4 5 9 10 In most cases, only a small number of patients received treatment, however, or the reports are available only in the form of abstracts. Until now only one full paper from a radiological centre with memory metal stents (Ultraflex) in a larger number of patients (40) has been published.1 Memory metal endoprostheses of the Ultraflex type, which have recently been redesigned have been available in Germany in the improved version since August 1993. We report on our preliminary clinical experiences in implementing the new version of this stent in 30 consecutive patients.
Methods
Patients From August 1993 to August 1994 a total of 30 patients with incurable tumours of the oesophagus and the cardia were treated with self expanding metal endoprostheses of the memory metal stent type (Ultraflex, Microvasive Boston Scientific, MA, USA) in a prospective study. Twenty five patients were men and five were women. Their age ranged from 43 to 90 years with a mean (SD) of 65 (12) years. Histologically, a squamous cell carcinoma was found in 15 of 30 patients (50%), an adenocarcinoma in eight (27%), and an anaplastic carcinoma in two (7%) patients. One patient had lung cancer and another patient a metastatic cancer of the thyroid gland, both leading to an oesophageal obstruction. A histological examination of the tumour was omitted in three patients, because the malignancy had been conclusively confirmed by imaging techniques or by assessment of the course of the disease. Most patients (19) showed the obstructive lesion in the distal part of the oesophagus and the gastro-oesophageal junction. In five patients, the tumour was located in the mid-section and in two patients in the proximal part of the oesophagus. Two other patients had a tumour recurrence at the anastomosis of an earlier gastrectomy and oesophageal resection, respectively. The length of the tumour stenosis ranged from 3 to 18 cm (mean (SEM) 7 (3) cm).
Seven of 30 patients suffered from dysphagia for solid foods alone (23%), 11 patients (37%) for semisolid foods, and 12 patients (40%) for liquids. Most of the patients (24 of 30) had received previous treatment in the form of bougienage (19), laser therapy (eight), dilatation (one), and percutaneous endoscopically controlled gastrotomy (PEG) (three).
Stent materials and implantation technique
The self expanding metal prostheses used were memory metal stents (Ultraflex), designed for use within the oesophagus. The stent mesh is knitted from a single elastic wire, consisting of a nickel-titanium alloy (nitinol), also referred to as memory metal. When fully expanded, the stent has a diameter of 18 mm. The upper end is shaped like a tulip and measures 20 mm in diameter to improve the anchoring of the stent to the oesophageal wall. The prosthesis is available in three different lengths (7 cm, 10 cm, and 15 cm).
The prosthesis is mounted in a compressed state on the stent delivery system consisting of a stabiliser and is encased in a soluble gelatin. The stabiliser is fairly flexible and enclosed in a transparent plastic protective sheath with an outer diameter of 8 mm. The tapered tip at the distal end of the stabiliser, which has a lumen for a 0.038 guidewire, favours the delivery system pass through tight strictures. Four radio-opaque markers are attached to the stabiliser. The two outer ones mark the ends of the stent in the compressed state and the inner ones mark the ends of the expanded and therefore shortened stent. To release the stent, the proximal end of the stabiliser is held steady while the outer plastic sheath is evenly retracted. Upon exposure to oesophageal fluids, the gelatin dissolves within three to five minutes, resulting in expansion of the stent. Finally the inner stabiliser is removed.
Before stent implantation, patients received a mild sedoanalgesia with 5-10 mg diazepam and 50 mg meperidine intravenously. If necessary, the stenosis was pretreated by laser coagulation or bougienage, or both, until a satisfactory dilatation was achieved. Generally, a diameter of 12 mm was considered to be large enough to permit an endoscope with a minimum diameter of 10 mm to pass the stricture easily. After placement of a guidewire the entire length of the tumour stenosis was precisely measured while retracting the endoscope to calculate the correct stent length. Ideally, the stent should extend beyond the margins of the tumour at both ends by at least 3 cm. In case of stenosis in the gastro-oesophageal junction the proximal extension of the stent ends beyond the tumour margins should be at least 5 cm. With patients in a supine position, metallic markers were attached to the patient's skin at the distal and proximal border of the stricture. Under fluoroscopic control the stents were inserted over the guidewire in the way described. Immediately after stent placement an endoscopy was performed to verify the position, expansion, and anchoring of the proximal part of the stent. A complete passage through the stent was not forced because of the increased risk of stent displacement. The stent opening was checked endoscopically and radiologically one or two days after implantation (Fig 1) . If the endoprosthesis had not expanded sufficiently one day after implantation, the stent diameter was increased by means of balloon dilatation. The balloons were 15 and 18 mm in diameter and 8 cm in length (Rigiflex, Microvasive Boston Scientific, Watertown, MA, USA). Until the stent position was checked the patients were advised to take only liquids. Thereafter they had semisolid or solid foods, as individually tolerated and were advised to avoid stringy meat, green salads, and cheese spread, even if they had no dysphagia after stent implantation. Antireflux measures (proton pump inhibitor and a prokinetic agent) were given to patients whose prosthesis extended beyond the gastro-oesophageal junction. In accordance with the study protocol an endoscopic follow up examination and a short medical history were carried out every four weeks. Only four patients refused to undergo further endoscopies and were these 17 patients, whereas the remaining 12 patients (40°/) required dilatation treatment (Table II) . After an average of two dilatation sessions using a balloon catheter (range 1-5) eight of 12 stents had expanded completely, that is to say, to a point where a standard endoscope could have been moved through the stent without resistance. One of four patients with an insufficient expansion despite dilatation died three days after stent implantation and before completion of the dilatation treatment in consequence of a progressive Korsakow syndrome and a blood sugar disturbance. The exact cause of death could not be established because the relatives of the deceased patient did not consent to a necropsy.
In the second patient a sufficient stent expansion could not be achieved, because the length of the tumour -which had reached an advanced stage -was 17 cm. In the third patient a pronounced compression of the tumour from outside was ascertained, which could be treated only partially by dilatation treatment. In another patient with a remaining stenosis in the region of the cardia despite five dilatation sessions after stent placement a Gianturco-Z-stent was successfully implanted, which showed a sufficient expansion with 48 hours (Fig 2) . Eight patients complained of chest pain, three of them had acute pain sensations over a period of several days, and one of them also had a foreign body sensation. Three patients suffered from severe heartburn despite antireflux measures and acid inhibition over several days, which disappeared with increased oral intake of food. One patient reported intermittent moderate pyrosis (Table II) 
